Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Diehl, A. Boer, S. Schoenberger, E. Voort, T. Schumacher, C. Melief, R. Offringa, R. Toes (1999)
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacyNature Medicine, 5
P. Dong, C. Brunn, Ho Rj (1995)
Cytokines as vaccine adjuvants. Current status and potential applications.Pharmaceutical biotechnology, 6
A. Heath, Wei Wu, M. Howard (1994)
Monoclonal antibodies to murine CD40 define two distinct functional epitopesEuropean Journal of Immunology, 24
Hixon Hixon, Blazar Blazar, Murphy Murphy (2000)
Acute toxicity of CD40 stimulation following syngeneic bone marrow transplantationRole Interferon-Gamma Exp Hematol, 28
Heath Aw (1995)
Cytokines as immunological adjuvants.Pharmaceutical biotechnology, 6
Barr Barr, Heath Heath (2001)
Functional activity of anti‐CD40 mAbs correlates to the position of binding relative to CD154Immunology, 102
R. French, H. Chan, A. Tutt, M. Glennie (1999)
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell helpNature Medicine, 5
P. Dullforce, D. Sutton, A. Heath (1998)
Enhancement of T cell-independent immune responses in vivo by CD40 antibodiesNature Medicine, 4
J. Hixon, B. Blazar, M. Anver, R. Wiltrout, W. Murphy (2001)
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 7 3
W. Ferlin, T. Weid, F. Cottrez, D. Ferrick, R. Coffman, M. Howard (1998)
The induction of a protective response in Leishmania major‐infected BALB/c mice with anti‐CD40 mAbEuropean Journal of Immunology, 28
L. Erickson, L. Vogel, M. Cascalho, J. Wong, M. Wabl, Brigit Durell, R. Noelle (2000)
B cell immunopoiesis: visualizing the impact of CD40 engagement on the course of T cell‐independent immune responses in an Ig transgenic systemEuropean Journal of Immunology, 30
A. Ninomiya, K. Ogasawara, K. Kajino, A. Takada, H. Kida (2002)
Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.Vaccine, 20 25-26
Rajesh Gupta, Edgar Relyveld, E. Lindblad, Bernard Bizzini, Shlomo Ben-Efraim, Chander Gupta (1993)
Adjuvants--a balance between toxicity and adjuvanticity.Vaccine, 11 3
C. Kooten, J. Banchereau (1997)
Functions of CD40 on B cells, dendritic cells and other cells.Current opinion in immunology, 9 3
P. Dempsey, Michael Allison, S. Akkaraju, C. Goodnow, D. Fearon (1996)
C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired ImmunityScience, 271
伊藤 大祐 (2000)
Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
Dana Baiu, J. Prechl, Andrey Tchorbanov, Hector Molina, A. Erdei, Andrei Sulica, Peter Capel, Wouter Hazenbos (1999)
Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors.Journal of immunology, 162 6
L. Corey, A. Langenberg, R. Ashley, R. Sekulovich, A. Izu, J. Douglas, H. Handsfield, T. Warren, L. Marr, S. Tyring, Richard DiCarlo, A. Adimora, P. Leone, C. Dekker, R. Burke, Wai Leong, S. Straus, S. Straus (1999)
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.JAMA, 282 4
E. Sotomayor, I. Borrello, E. Tubb, F. Rattis, H. Bien, Zhengbin Lu, S. Fein, S. Schoenberger, H. Levitsky (1999)
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40Nature Medicine, 5
J. Gordon, J. Pound (2000)
Fortifying B cells with CD154: an engaging tale of many huesImmunology, 100
C. Vinuesa, I. Maclennan, M. Holman, G. Klaus (1999)
Anti‐CD40 antibody enhances responses to polysaccharide without mimicking T cell helpEuropean Journal of Immunology, 29
T. Barr, A. Heath (1999)
Enhanced In Vivo Immune Responses to Bacterial Lipopolysaccharide by Exogenous CD40 StimulationInfection and Immunity, 67
Corey Corey, Langenberg Langenberg, Ashley Ashley (1999)
The Chiron HSV Vaccine Study Group. Recombinant glycoprotein vaccine for the prevention of genital HSV‐2 infection: Two randomized controlled trialsJAMA, 282
T. Barr, A. Heath (2001)
Functional activity of CD40 antibodies correlates to the position of binding relative to CD154Immunology, 102
D. Ito, K. Ogasawara, K. Matsushita, T. Morohashi, K. Namba, N. Matsuki, N. Kitaichi, Y. Inuyama, M. Hosokawa, E. Nakayama, K. Iwabuchi, K. Onoé (2000)
Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies.Immunobiology, 201 5
G. Carayanniotis, B. Barber (1987)
Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHCNature, 327
J. Hixon, M. Anver, B. Blazar, A. Panoskaltsis‐Mortari, R. Wiltrout, W. Murphy (2002)
Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 8 6
(2000)
Bethesda, MD: National Institute of Allergy and Infectious Diseases National Institutes of Health
J. Hixon, B. Blazar, W. Murphy (2000)
Acute toxicity of CD40 stimulation following syngeneic bone marrow transplantationExperimental Hematology, 28
L. French, J. Tschopp (1999)
The TRAIL to selective tumor deathNature Medicine, 5
A. Kay (1977)
Practical ImmunologyJournal of Clinical Pathology, 30
J. Banchereau, F. Bazan, D. Blanchard, F. Brière, J. Galizzi, C. Kooten, Yong‐jun Liu, F. Rousset, S. Saeland (1994)
The CD40 antigen and its ligand.Annual review of immunology, 12
Summary There is great potential for novel vaccines based on recombinant proteins and synthetic peptides. Unfortunately these antigens often lack the immunogenicity of whole, killed pathogens used in traditional vaccines. Thus there is strong interest in the identification of immunological adjuvants with low reactogenicity, but high potency, to enhance immune responses and realize the potential of these new vaccine strategies. CD40 antibodies have been shown to have adjuvant effects when administered at very high doses. These large doses are impractical and induce a cascade of cytokine release giving rise to septic shock‐like symptoms, as well as splenomegaly and polyclonal antibody production. We show here that a very small amount of CD40 antibody can exhibit potent adjuvant effects when attached to soluble antigen. The lack of detectable systemic effects indicates that this method may be a powerful and practical means of enhancing the efficacy of recombinant vaccines.
Immunology – Wiley
Published: May 1, 2003
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.